Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia

Inclusion Criteria:

1. Patient aged 20-80 years who has hypertension and hyperlipidemia

2. Patient who has a Hypertension

3. Patient who has a Hyperlipidemia according to NCEP-ATP III guideline(2004)

4. Patient who signed the Informed Consent Form after receiving an explanation on thepurpose, methods, and effect of the study

Exclusion Criteria:

1. If blood pressure and fasting serum lipid level measured at screening and Visit 2 (0week) satisfy the following criteria 1) sitSBP≥180mmHg or sitDBP≥110mmHg (For highrisk group, sitSBP≥ 160mmHg or sitDBP ≥100mmHg ) 2) LDL-C>250mg/dL , or TG≥ 400mg/dL

2. If sitSBP difference between the right and left arms >20mmHg or sitDBP differencebetween the right and left arms > 10mmHg at screening

3. When blood pressure is repeatedly measured from the selected arm at screening, ifsitSBP difference ≥ 20mmHg or sitDBP difference ≥10mmHg

4. Patient with orthostatic hypotension accompanying symptoms at screening (decrease insitDBP ≥10mmHg or decrease in sitSBP ≥ 20mmHg )